Epithelial Ovarian Cancer: A Five Year Review

Arnaoutoglou, Christos; Dampala, Kalliopi; Anthoulakis, Christos; Papanikolaou, Evangelos; Tentas, Ioannis; Dragoutsos, Georgios; Machairiotis, Nikolaos; Ioannidis, Aris; Matthaios, Dimitris; Perdikouri, Eleni Isidora; Giannakidis, Dimitrios; Sardeli, Chrysanthi; Petousis, Stamatios; Οικονόμου, Παναγούλα; Nikolaou, Charalampos; Charalampidis, Charalampos; Sapalidis, Konstantinos

doi:10.3390/medicina59071183

Cited by 10 publications

(7 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ~70% of patients with advanced stages of EOC worldwide will experience relapse within 2 years ( 4 , 5 ). Furthermore, the majority of patients with recurrent cancer exhibit resistance to platinum-based chemotherapy, resulting in a low 5-year survival rate ( 6 ). Therefore, comprehending the resistance mechanisms of platinum-based chemotherapy is advantageous in enhancing the prognosis of patients with EOC.…”

Section: Introductionmentioning

confidence: 99%

HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β

Wang,

Zheng,

Zhao

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

The aim of the present study was to investigate the impact and mechanism of high mobility group box 1 (HMGB1) on the regulation of cell migration and invasion in A2780/DDP cisplatin-resistant ovarian cancer cells. After transfecting small interfering (si)RNA-HMGB1 into A2780/DDP cells, Transwell migration and invasion assays were conducted to assess alterations in the cell migratory and invasive abilities. Additionally, western blotting analyses were performed to examine changes in HMGB1, phosphorylated (p)-GSK-3β, GSK-3β, E-cadherin and vimentin expression levels. The results of the present study demonstrated that the migratory and invasive abilities of A2780/DDP cells were significantly higher compared with those of A2780 cells. Additionally, the expression levels of HMGB1, p-GSK-3β and the mesenchymal phenotype marker, vimentin, in A2780/DDP cells were significantly elevated relative to the levels in A2780 cells. Conversely, the expression level of the epithelial phenotype marker, E-cadherin, was markedly decreased compared with that in A2780 cells. Following transfection of A2780/DDP cells with siRNA-HMGB1, there was a significant reduction in the rate of cell migration and invasion. Simultaneously, the expression levels of HMGB1, p-GSK-3β and vimentin were downregulated while the level of E-cadherin was upregulated. It was therefore concluded that the high expression of HMGB1 in A2780/DDP cells enhanced the cell migration and invasion abilities by facilitating epithelial to mesenchymal transition via GSK-3β.

show abstract

Section: Introductionmentioning

confidence: 99%

HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β

Wang,

Zheng,

Zhao

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…The intracellular mechanisms of ovarian carcinogenesis are multifactorial, so the treatment strategy includes chemotherapy, immunotherapy, and therapy aimed at neoangiogenesis [5,6]. Drug resistance is a bottleneck in ovarian cancer treatment despite the application of new drugs.…”

Section: Introductionmentioning

confidence: 99%

Activity of NAD(P)H-Oxidoreductases in Ovarian Cancer

Fedorova,

Voznesensky,

Sosnova

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Reactive oxygen species (ROS) play an important and controversial role in carcinogenesis. Microsomal redox chains containing NADH- and NADPH-dependent oxidoreductases are among the main sites of intracellular ROS synthesis, but their role in the oxidative balance has not been fully studied. Here, we studied the activity of cytochrome b5 reductase (CYB5R) and cytochrome P450 reductase (CYPOR) in ovarian cancer tissues and cells isolated from peritoneal fluid, along with the antioxidant capacity of peritoneal fluid. We used the developed a chemiluminescence assay based on stimulation with NADH and NADPH, which reflects the activity of CYB5R and CYPOR, respectively. The activity of CYB5R and CYPOR was significantly higher in moderately and poorly differentiated ovarian adenocarcinomas compared with well-differentiated adenocarcinomas and cystadenomas. For the chemotherapy-resistant tumors, the activity of tissue CYB5R and CYPOR was lower compared to the non-resistant tumors. In the peritoneal fluid, the antioxidant capacity significantly increased in this series, benign tumors < well-differentiated < moderately and poorly differentiated adenocarcinomas, so the antioxidant excess was observed for moderately and poorly differentiated adenocarcinomas. The antioxidant capacity of peritoneal fluid and the activity of CYB5R and CYPOR of cells isolated from peritoneal fluid were characterized by a direct moderate correlation for moderately and poorly differentiated adenocarcinomas. These results indicate the significant role of NAD(P)H oxidoreductases and the antioxidant potential of peritoneal fluid in cancer biochemistry. The parameters studied are useful for diagnostics and prognostics. The developed assay can be used to analyze CYB5R and CYPOR activity in other tissues and cells.

show abstract

“…Ovarian cancer is the deadliest gynecological malignancy, the second most common malignancy in women over the age of 40, and the fifth leading cause of cancer death in women. 1 According to the latest statistics from the National Cancer Center, ovarian cancer accounts for approximately 2.93% of new cases and 2.24% of deaths in China each year. 2 In the past decade, the mortality of ovarian cancer in China has shown an upward trend mainly because of its hidden onset and lack of accurate and effective early screening methods.…”

Section: Introductionmentioning

confidence: 99%

The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy

Lin,

Zou,

Nong

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundTumor immunotherapy has become an important adjuvant therapy after surgery, radiotherapy, and chemotherapy. In recent years, the role of tumor‐associated antigen (TAA) in tumor immunotherapy has become increasingly prominent. Cancer‐testis antigen (CTA) is a kind of TAA that is highly restricted in a variety of tumors and can induce an immune response.AimsThis review article aimed to evaluate the role of CTA on the progression of ovarian cancer, its diagnostic efficacy, and the potential for immunotherapy.MethodsWe analyzed publications and outlined a comprehensive of overview the regulatory mechanism, immunogenicity, clinical expression significance, tumorigenesis, and application prospects of CTA in ovarian cancer, with a particular focus on recent progress in CTA‐based immunotherapy.ResultsThe expression of CTA affects the occurrence, development, and prognosis of ovarian cancer and is closely related to tumor immunity.ConclusionCTA can be used as a biomarker for the diagnosis and prognosis evaluation of ovarian cancer and is an ideal target for antitumor immunotherapy. These findings provide novel insights on CTA in the improvement of diagnosis and treatment for ovarian cancer. The successes, current challenges and future prospects were also discussed to portray its significant potential.

show abstract

Epithelial Ovarian Cancer: A Five Year Review

Cited by 10 publications

References 82 publications

HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β

HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β

Activity of NAD(P)H-Oxidoreductases in Ovarian Cancer

The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy

Contact Info

Product

Resources

About